Endothelial dysfunction and complement activation are independently associated with disease duration in patients with systemic vasculitis

Microvasc Res. 2024 Jul:154:104692. doi: 10.1016/j.mvr.2024.104692. Epub 2024 May 4.

Abstract

Objectives: Systemic vasculitis is a heterogenous group of autoimmune diseases characterized by enhanced cardiovascular mortality. Endothelial dysfunction is associated with accelerated vascular damage, representing a core pathophysiologic mechanism contributing to excess CV risk. Recent studies have also shown that complement activation holds significant role in the pathogenesis of Anti-Neutrophilic Cytoplasmic Autoantibody (ANCA) -associated vasculitis (AAV). Given the potential crosstalk between the endothelium and complement, we aimed to assess, for the first time simultaneously, easily accessible biomarkers of endothelial dysfunction and complement activation in SV.

Methods: We measured circulating endothelial microvesicles (EMVs) and soluble complement components representative of alternative, classical and terminal activation (C5b-9, C1q, Bb fragments, respectively) in a meticulously selected group of patients with systemic vasculitis, but without cardiovascular disease. Individuals free from systemic diseases, who were matched with patients for cardiovascular risk factors(hypertension, diabetes, smoking, dyslipidemia), comprised the control group.

Results: We studied 60 individuals (30 in each group). Patients with systemic vasculitis had elevated EMVs, higher levels of C5b-9 [536.4(463.4) vs 1200.94457.3), p = 0.003] and C1q [136.2(146.5 vs 204.2(232.9), p = 0.0129], compared to controls [232.0 (243.5) vs 139.3(52.1), p < 0.001]. In multivariate analysis both EMVs and C5b-9 were independently associated with disease duration (p = 0.005 and p = 0.004 respectively), yet not with disease activity.

Conclusion: Patients with systemic vasculitis exhibit impaired endothelial function and complement activation, both assessed by easily accessible biomarkers, even in the absence of cardiovascular disease manifestations. EMVs and soluble complement components such as C5b-9 and C1q could be used as early biomarkers of endothelial dysfunction and complement activation, respectively, in clinical practice during the course of SV, yet their predictive value in terms of future cardiovascular disease warrants further verification in appropriately designed studies.

Keywords: Alternative pathway; Anca-associated vasculitis; Autoimmune disease; Bb; Behçet's disease; C1q; C5b-9; Classical pathway; Complement; Endothelial dysfunction; Endothelial microvesicles; Systemic vasculitis.

MeSH terms

  • Adult
  • Aged
  • Biomarkers* / blood
  • Case-Control Studies
  • Cell-Derived Microparticles / immunology
  • Cell-Derived Microparticles / metabolism
  • Cell-Derived Microparticles / pathology
  • Complement Activation*
  • Complement C1q / immunology
  • Complement C1q / metabolism
  • Complement Membrane Attack Complex / immunology
  • Complement Membrane Attack Complex / metabolism
  • Endothelial Cells / immunology
  • Endothelial Cells / metabolism
  • Endothelial Cells / pathology
  • Endothelium, Vascular* / immunology
  • Endothelium, Vascular* / physiopathology
  • Female
  • Humans
  • Male
  • Middle Aged
  • Systemic Vasculitis / blood
  • Systemic Vasculitis / diagnosis
  • Systemic Vasculitis / immunology
  • Systemic Vasculitis / physiopathology
  • Time Factors

Substances

  • Biomarkers
  • Complement Membrane Attack Complex
  • Complement C1q